Emily Tomasulo, DO, FACP

Medical Oncology, Hematology
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital
View 1 additional location
Make an appointmentCall 800-789-7366
Headshot of Emily Tomasulo, DO, FACP
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Medical School: Philadelphia College of Osteopathic Medicine
  • Residency: Pennsylvania Hospital
  • Fellowship: National Institutes of Health

Spoken languages

English
English

Reviews

Average Rating

512 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
dr. tomasulo is great
Anonymous
May 2026
good listener
Anonymous
May 2026
all in all excellent experience
Anonymous
May 2026
she cares and is skilled

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Tomasulo is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Chong EA, Tomasulo EB, Barta SK 2026 Update on the Management of Diffuse Large B-Cell Lymphoma , American Journal of Hematology, 101(4): 2026,832-863

Emily Tomasulo, Andy Itsara, Mark Haigney, Douglas R. Rosing, Inhye E. Ahn, Cody Peer, Beth A. Kozel, Teresa Luperchio, Grace Ge, William D. Figg, Adrian Wiestner, and Clare Sun Sudden Death and Asymptomatic Arrhythmia in CLL Patients Treated with Ibrutinib , Heart Rhythm: 2025

Christopher Pleyer, Emily Tomasulo, et. al Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia , Blood Supplement, American Society of Hematology Annual Meeting, San Diego, CA.: 2024

Emily B. Tomasulo, Dylan Therwhanger, Emeline R. Chong, Mitchell E. Hughes, Michael Fradley, and Stephen J. Schuster Resolution of ibrutinib-associated hypertension with transition to alternate covalent BTKi , Blood Supplement, American Society of Hematology Annual Meeting, San Diego, CA.: 2024

Emily Tomasulo, Shira Paul, Rui Mu, Xin Tian, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL , Leukemia & Lymphoma, 64(14): 2023,2306-2315.

Itsara A, Sun C, Bryer E, et al. Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study , Blood Supplement, American Society of Hematology, Washington, DC: 2023

Emily Tomasulo Chronic Lymphocytic Leukemia Chapter , Bethesda Handbook of Hematology: 2023

Bryer E, Itsara A, Ahn I et al. Ibrutinib-associated sudden death in patients with CLL , Blood, American Society of Hematology, Orlando, FL., 140(Supplement 1): 2022

Bryer EJ, Destefano C, Kazandjian D. Current and prospective antibody-based therapies in multiple myeloma , Semin Oncol, 49(1): 2022,41-47

Bryer EJ, Stein E, Goldberg S. Multivessel Coronary Artery Disease , Mayo Clinic Proceedings: Innovations, Quality, and Outcomes.: 2020